Catlin Nalley

Freelance Writer and Editor at Freelance

Freelance Writer

Featured in: Favicon

lww.com

advanceweb.com Favicon

reviewofoptometry.com Favicon

reviewofophthalmology.com Favicon

reviewofcontactlenses.com Favicon

journals.lww.com Favicon

nursing.advanceweb.com

Articles

Take On Advanced Corneal Care Techniques

1 week ago | reviewofoptometry.com | Catlin Nalley

In the April 2025 issue of Review of Optometry—the magazine's 12th annual cornea report—learn effective strategies for managing herpetic keratitis, delve into advanced imaging techniques for early detection of keratoconus and get expert tips for specializing in advanced corneal care. Check out the other articles featured in this issue:My Patient Has Herpetic Keratitis… Now What?
How to Meet the Growing Demand for Myopia Management

1 month ago | reviewofoptometry.com | Catlin Nalley

Myopia is on the rise globally, with projections indicating that half of the world’s population will be affected by 2050. As prevalence increases, so does the need for specialized care to slow its progression and mitigate long-term ocular health risks. Optometrists who embrace myopia management have a unique opportunity to address a growing public health challenge while expanding their clinical expertise and practice offerings through evidence-based interventions that make a lasting impact.
Building a Specialty in Pediatric Eye Care: A Roadmap for Optometrists

2 months ago | reviewofoptometry.com | Catlin Nalley

Specialty care plays a critical role in the evolving field of optometry. As primary eyecare providers, optometrists are in a position to identify and address complex visual and ocular health issues that can strongly impact patients’ lives. Developing a niche specialty enhances the level of care provided and helps build a practice that stands out.
A Look at Advancements in Thyroid Cancer Research & Treatment : Oncology Times

Dec 5, 2024 | journals.lww.com | Catlin Nalley |Philip Bernard

Home > Blogs > Oncologists’ Guide to Genomics > A Look at Advancements in Thyroid Cancer Research & Treatmen... Stay current on the latest trends in genomics and molecular diagnostics for oncology.
The Clinical Trials That Changed Eye Care

Nov 15, 2024 | reviewofoptometry.com | Catlin Nalley |James Wolffsohn |Jennifer Craig |Lyndon Jones

Medical statistics are only meaningful if you know how they’re calculated and why. To help ODs feel more confident interpreting clinical study findings and stats, Review of Optometry published a four-part series on scientific research and how it relates to clinical practice.
The Clinical Trials That Changed Eye Care

Nov 15, 2024 | reviewofoptometry.com | Catlin Nalley |James Wolffsohn |Jennifer Craig |Lyndon Jones

Medical statistics are only meaningful if you know how they’re calculated and why. To help ODs feel more confident interpreting clinical study findings and stats, Review of Optometry published a four-part series on scientific research and how it relates to clinical practice.
An Option to Mitigate Nausea & Vomiting Among Breast Cancer Patients

Sep 17, 2024 | focusononcology.com | Catlin Nalley

By Catlin NalleyA new analysis suggests that olanzapine (5 mg for 6 days) coupled with 5-hydroxytryptamine type 3-receptor antagonist (5-HT3RA) and dexamethasone is an effective approach to reduce delayed and persistent nausea and vomiting among metastatic breast cancer patients treated with trastuzumab deruxtecan (T-DXd).
New Data Supports Safety of Breastfeeding Following Breast Cancer

Sep 15, 2024 | focusononcology.com | Catlin Nalley

By Catlin NalleyResearchers found that breastfeeding was feasible for the majority of patients with hormone receptor-positive breast cancer who gave birth in the POSITIVE trial. Nearly two-thirds breastfed and more than 50 percent did so for more than 4 months, according to findings presented during ESMO 2024 Congress in Barcelona (Abstract 1814O).
Pembrolizumab + Chemo Significantly Improves OS in High-Risk, Early-Stage TNBC

Sep 15, 2024 | focusononcology.com | Catlin Nalley

By Catlin NalleyOverall survival (OS) results from the Phase III, KEYNOTE-522 study showed a statistically significant and clinically meaningful improvement in OS among patients with high-risk, early-stage triple-negative breast cancer (TNBC) who were treated with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab versus those who received neoadjuvant chemotherapy alone (Abstract LBA4).
Devices You Might Not Have: Are They a Good Fit?

Sep 14, 2024 | reviewofoptometry.com | Catlin Nalley

Optometrists today have more tools than ever at their disposal to help detect, treat and manage disease. To help you keep up with the constant innovation, the September 2024 issue of Review of Optometry—our 47th annual technology report—reviews the pros and cons of telehealth in optometry, new devices in eye care and the future of remote monitoring. Plus, find the results of our annual tech survey to discover which clinical instruments your peers are buying or desiring.